ENVERIC BIOSCIENCES, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $43.0M | $48.6M | $36.1M | $20.3M | $6.1M | — | — | — |
| Cost of Revenue | $34.0M | $38.4M | $29.2M | $13.4M | $5.2M | — | — | — |
| Gross Profit | $9.0M | $10.2M | $6.9M | $6.9M | $911.0K | — | — | — |
| Gross Margin | 20.9% | 21.1% | 19.2% | 33.9% | 14.8% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | $55.1K | — | — | — | — | — |
| SG&A Expense | $10.8M | $18.5M | $9.4M | $5.7M | $-32.8K | $-27.2K | $22.7K | $31.4K |
| Operating Income | $-7.1M | $-10.9M | $-5.4M | $-794.0K | $32.8K | $27.2K | $-22.7K | $-31.4K |
| Operating Margin | -16.6% | -22.4% | -14.9% | -3.9% | 0.5% | — | — | — |
| Interest Expense | $729.9K | $575.0K | $751.1K | $238.5K | — | — | — | — |
| Pretax Income | $-10.5M | $-11.5M | $-6.5M | — | $-32.8K | $1.3K | $-22.7K | $-31.4K |
| Income Tax Expense | $6.3M | $-2.4M | $-3.7M | $-128.5K | $833 | $1.5K | $1.9K | $2.0K |
| Net Income | $-16.9M | $-9.1M | $-2.8M | $-814.1K | $-33.6K | $-161 | $-24.6K | $-33.4K |
| Net Margin | -39.3% | -18.7% | -7.7% | -4.0% | -0.5% | — | — | — |
| EPS (Basic) | $-0.14 | $-0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.14 | $-0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 137.0M | 2.16B | 1.88B | 1.60B | 2.19B | 1.75B | 1.75B | 1.22B |
| Shares Outstanding (Diluted) | 137.0M | 2.16B | 1.88B | 1.60B | 2.19B | 1.75B | 1.75B | 1.22B |
| Dividends Per Share | — | — | — | — | — | — | — | — |